BioNexus Gene Lab (BGLC) Balance Sheet: Assets & Liabilities

BioNexus Gene Lab (BGLC) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2026), BioNexus Gene Lab reported total assets of $9.25M and total liabilities of $637.86K. Shareholders' equity was $8.61M. Total debt stood at $176.05K against $4.04M in cash and short-term investments, a net cash position of $3.86M. That puts debt-to-equity at 0.02.

BioNexus Gene Lab Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for BioNexus Gene Lab Corp. (BGLC) - Annual data in millions USD
Breakdown	FY 2026	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	2.38	4.38	2.62	0.61	2.12	2.79	0.86	0.66	0.84
Short-Term Investments	1.66	0.00	3.31	1.51	0.00	0.00	0.00	0.60	0.00
Cash & Short-Term Investments	4.04	4.38	5.93	2.12	2.12	2.79	0.86	1.26	0.84
Accounts Receivable	0.51	1.58	0.80	2.87	3.36	4.00	0.00	0.00	0.00
Inventory	0.68	1.39	1.14	0.98	1.52	1.18	0.01	0.02	0.03
Other Current Assets	0.08	0.08	0.12	0.03	0.08	0.02	0.01	0.02	0.13
Total Current Assets	5.45	7.43	8.05	6.02	7.08	7.99	0.88	1.30	1.00
Non-Current Assets
Property, Plant & Equipment (Net)	1.78	1.74	1.65	1.57	1.68	1.85	0.34	0.34	0.27
Long-Term Investments	2.03	1.27	1.70	1.15	0.75	0.28	0.01	0.01	0.00
Other Non-Current Assets	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.00
Total Non-Current Assets	3.80	3.00	3.35	2.72	2.49	2.13	0.35	0.35	0.27
Total Assets	9.25	10.43	11.40	8.74	9.57	10.12	1.23	1.65	1.27
Current Liabilities
Accounts Payable	0.00	1.50	1.40	1.86	2.01	3.17	0.00	0.00	0.04
Short-Term Debt	0.06	0.05	0.05	0.02	0.04	0.05	0.03	0.02	0.00
Accrued Liabilities	0.40	0.28	0.18	0.10	-	-	-	-	-
Deferred Revenue	0.01	0.10	0.00	0.02	0.11	0.00	0.00	0.00	0.00
Other Current Liabilities	0.45	0.30	0.18	0.13	0.07	0.10	0.02	0.04	1.14
Total Current Liabilities	0.52	1.95	1.63	2.00	2.33	3.37	0.05	0.06	1.17
Non-Current Liabilities
Long-Term Debt	0.12	0.16	0.10	0.04	0.04	0.08	0.06	0.06	0.00
Deferred Tax Liabilities	0.00	0.00	0.01	0.03	0.03	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	0.00	0.00	0.01	0.03	0.00	0.00	0.00	0.00	0.00
Total Non-Current Liabilities	0.12	0.16	0.11	0.07	0.07	0.08	0.06	0.07	0.00
Total Liabilities	0.64	2.11	1.74	2.08	2.39	3.45	0.11	0.13	1.18
Stockholders' Equity
Common Stock	20.17	17.33	17.19	10.93	10.78	10.78	6.48	6.65	5.21
Retained Earnings	-6.43	-3.44	-1.84	1.16	1.51	0.76	-0.33	-0.09	-0.11
Accumulated Other Comprehensive Income	-0.12	-0.56	-0.68	-0.41	-0.10	0.13	-0.02	-5.04	0.01
Additional Paid-in Capital	-5.01	-5.01	-5.01	-5.01	-5.01	-5.01	-5.01	0.00	-5.01
Shares Outstanding	2.42	1.80	1.77	1.45	1.43	-	-	-	-
Total Stockholders' Equity	8.61	8.32	9.66	6.67	7.18	6.66	1.12	1.52	0.09
Total Liabilities & Equity	9.25	10.43	11.40	8.74	9.57	10.12	1.23	1.65	1.27

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About BioNexus Gene Lab Balance Sheet

How much debt does BioNexus Gene Lab have?

BioNexus Gene Lab had total debt of $176.05K as of Dec 31, 2025, against $4.04M in cash and short-term investments. Its debt-to-equity ratio was 0.02.

What are BioNexus Gene Lab's total assets?

BioNexus Gene Lab reported total assets of $9.25M as of Dec 31, 2025. Total liabilities were $637.86K.

What is BioNexus Gene Lab's shareholders' equity?

BioNexus Gene Lab's shareholders' equity was $8.61M as of Dec 31, 2025, or about $3.56 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition